Sunday 18 October 2026
Export LCTX’s income statement to Excel — free account
Lineage Cell Therapeutics, Inc.
LCTX Healthcare Biotechnology
Lineage Cell Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.6 million, up 53.2% from fiscal 2024. In the quarter to June 2026, revenue fell 61.3%, EPS grew 104.8%, free cash flow fell 32.4% and total debt fell 68.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.98
0.01
−1.01%
Follow LCTX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
10.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 3 | 3 | 3 | 2 | 3 | 6 | 0 | 5 | 5 |
Altman Z-Score |
12.18 | 12.17 | 2.80 | 1.90 | 8.15 | (0.28) | (1.89) | (2.91) | (3.48) | (2.91) |
P/S ratio |
52.25 | 66.21 | 23.15 | 36.85 | 144.62 | 92.84 | 14.20 | 21.04 | 10.54 | 26.40 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 323.29 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
4.86 | 14.99 | 1.04 | 1.69 | (0.54) | (4.63) | (7.17) | (11.06) | (8.51) | (12.27) |
Beneish M-Score |
(0.36) | 0.66 | (3.21) | 5.49 | (3.91) | 4,915.14 | (2.00) | 0.33 | (2.35) | (3.98) |
P/Operating CF |
(34.96) | (40.34) | (19.87) | (23.45) | (46.81) | (68.62) | (25.15) | (31.27) | (15.77) | (78.78) |
P/B ratio |
2.37 | 1.39 | 1.25 | 1.16 | 2.78 | 4.43 | 2.90 | 3.03 | 1.30 | 8.87 |
Price to Tangible BV |
2.57 | 1.45 | 1.30 | 2.48 | 7.06 | 12.07 | 14.33 | 39.30 | 5.06 | 394.55 |
EV/Sales |
48.66 | 55.21 | 17.01 | 28.13 | 121.87 | 79.41 | 10.27 | 17.08 | 5.51 | 22.57 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(6.81) | (6.26) | (2.75) | (3.10) | (11.27) | (14.63) | 142.64 | (5.35) | (2.27) | (17.37) |
EV/FCF |
(6.43) | (6.03) | (2.63) | (3.06) | (11.24) | (14.42) | 233.83 | (5.23) | (2.21) | (16.90) |
Quick Ratio |
2.70 | 5.99 | 5.06 | 8.42 | 5.35 | 2.32 | 3.06 | 2.02 | 3.47 | 4.99 |
Current Ratio |
2.90 | 6.20 | 5.34 | 8.86 | 5.66 | 2.37 | 3.16 | 2.14 | 3.65 | 5.20 |
Net Debt/EBITDA |
0.40 | 1.09 | 0.80 | 0.86 | 1.69 | 1.21 | 2.65 | 1.48 | 2.28 | 2.64 |
Debt/Assets |
1.03% | 0.09% | 0.10% | 0.06% | 0.02% | 0.02% | 0.07% | 0.09% | 0.06% | 0.03% |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.05 | 0.02 | 0.04 | 0.03 | 0.02 | 0.03 | 0.10 | 0.08 | 0.09 | 0.13 |
Operating CF/Net income |
(1.26) | 1.53 | 0.67 | 2.73 | 0.96 | 0.55 | (0.04) | 1.33 | 1.24 | 0.30 |
Capex/Depreciation |
(0.49) | (0.29) | (0.43) | (0.11) | (0.02) | (0.38) | (0.60) | (0.86) | (1.00) | (0.03) |
Interest Coverage |
(78.94) | (56.22) | 58.78 | (23.07) | 25.45 | (24,605.50) | 27.17 | 15.18 | 12.52 | 21.66 |
| 32.44% | (13.55%) | (35.86%) | (11.51%) | (20.01%) | (46.25%) | (32.27%) | (32.08%) | (26.77%) | (105.57%) | |
| 28.30% | (12.65%) | (33.46%) | (10.31%) | (17.69%) | (30.46%) | (17.62%) | (19.13%) | (17.37%) | (56.27%) | |
ROIC |
(33.73%) | (19.26%) | (42.40%) | (30.14%) | (30.84%) | (94.43%) | (99.51%) | (58.07%) | (45.86%) | 0.00% |
Return on Tangible Assets |
150.36% | (48.39%) | (129.99%) | (19.78%) | (49.33%) | (62.07%) | (56.27%) | (94.54%) | (47.39%) | (126.17%) |
Average Days of Receivables |
71.30 | 321.51 | 272.14 | 2,485.95 | 0.80 | 4,274.73 | 7.37 | 30.40 | 24.52 | 22.34 |
Research and Development Expense of Revenue |
609.59% | 694.74% | 420.11% | 510.61% | 674.53% | 781.25% | 95.13% | 175.57% | 131.30% | 121.80% |
Selling, General and Administrative Expense of Revenue |
479.93% | 576.11% | 495.71% | 683.67% | 852.74% | 419.53% | 153.08% | 193.43% | 191.29% | 126.82% |
Intangible Assets out of Total Assets |
0.07 | 0.04 | 0.03 | 0.47 | 0.53 | 0.33 | 0.46 | 0.57 | 0.51 | 0.38 |
Share Based Compensation of Revenue |
134.24% | 113.71% | 108.30% | 101.85% | 128.48% | 85.72% | 29.16% | 51.87% | 53.45% | 32.65% |
Graham Net Nets |
0.04 | 0.15 | 0.23 | 0.33 | 0.12 | 0.07 | 0.04 | 0.00 | 0.15 | (0.03) |
Graham Number |
3.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
9.88% | (5.50%) | (38.46%) | (4.49%) | (7.74%) | (10.61%) | (12.20%) | (11.93%) | (20.00%) | (16.77%) |
Free Cash Flow Yield |
(14.49%) | (13.82%) | (27.97%) | (24.94%) | (7.50%) | (5.93%) | 0.31% | (15.54%) | (23.63%) | (5.06%) |
Revenue per Share |
0.06 | 0.03 | 0.04 | 0.02 | 0.01 | 0.03 | 0.09 | 0.05 | 0.05 | 0.06 |
Operating CF per Share |
(0.43) | (0.27) | (0.24) | (0.22) | (0.13) | (0.14) | 0.01 | (0.17) | (0.12) | (0.08) |
Capex per Share |
(0.03) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.46) | (0.28) | (0.25) | (0.22) | (0.13) | (0.15) | 0.00 | (0.17) | (0.12) | (0.08) |
Cash per Share |
0.23 | 0.33 | 0.24 | 0.21 | 0.28 | 0.35 | 0.34 | 0.21 | 0.24 | 0.24 |
Shareholders Equity per Share |
1.34 | 1.43 | 0.73 | 0.76 | 0.63 | 0.55 | 0.42 | 0.36 | 0.38 | 0.19 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.34 | 1.43 | 0.73 | 0.76 | 0.63 | 0.55 | 0.42 | 0.36 | 0.38 | 0.19 |
Free Cash Flow |
(44.85) | (31.64) | (32.30) | (32.30) | (19.79) | (23.90) | 0.65 | (29.24) | (23.66) | (19.44) |
Working Capital |
16.80 | 35.74 | 29.55 | 51.03 | 36.23 | 64.43 | 41.02 | 20.48 | 37.02 | 47.79 |
Capital Expenditures |
(2.53) | (1.13) | (1.41) | (0.36) | (0.04) | (0.34) | (0.41) | (0.67) | (0.56) | (0.52) |
Net Current Asset Value |
13.59 | 33.65 | 26.94 | 43.29 | 31.18 | 27.90 | 8.27 | (0.55) | 14.79 | (10.08) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.43 | 0.33 | 0.28 | 0.10 | 0.02 | 0.08 | 0.03 | 0.08 | 0.06 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.94 | 0.71 | 0.56 | 0.38 | 0.34 | 0.18 | 0.12 | 0.35 | 0.25 | 6.03 |
Cash ROIC |
(29.00%) | (15.62%) | (26.24%) | (22.74%) | (14.48%) | (16.01%) | 0.50% | (29.96%) | (18.94%) | (19.61%) |
Accounts Receivable Turnover |
4.23 | 1.65 | 1.47 | 0.25 | 0.15 | 0.17 | 0.58 | 17.17 | 13.74 | 19.04 |
Accounts Payable Turnover |
0.04 | 0.03 | 0.05 | 0.07 | 0.06 | 0.08 | 0.04 | 0.09 | 0.06 | 0.02 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
7,283.69 | 12,423.04 | 7,811.24 | 4,629.83 | 6,459.08 | 7,158.97 | 4,315.82 | 3,410.66 | 5,941.63 | 17,952.50 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.40 | 2.10 | 3.38 | 13.83 | 11.97 | 25.42 | 25.57 | 0.52 | 0.69 | 0.76 |
Average Payables |
8.26 | 6.43 | 6.09 | 5.84 | 6.02 | 17.39 | 18.29 | 7.44 | 5.85 | 6.31 |
Average Assets |
118.62 | 157.91 | 137.45 | 113.57 | 116.71 | 141.25 | 149.10 | 112.34 | 107.12 | 112.90 |
Average Common Equity |
103.48 | 147.39 | 128.25 | 101.75 | 103.19 | 93.01 | 81.42 | 66.98 | 69.52 | 60.18 |
Columns are period end dates